Edding Genor Group Holdings Limited (HKG:6998)

Market Cap	3.03B
Revenue (ttm)	2.77B -2.3%
Net Income	444.30M +2.9%
EPS	0.26 +1.0%
Shares Out	1.99B
PE Ratio	5.83
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	162,000
Open	1.500
Previous Close	1.525
Day's Range	1.480 - 1.500
52-Week Range	1.420 - 5.600
Beta	0.90
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 28, 2026

About HKG:6998

Edding Genor Group Holdings Limited, together with its subsidiaries, engages in the research, development, manufacturing, and distribution of biopharmaceutical products in China, the United States, and internationally. The company offers GB491, a differentiated CDK4/6 inhibitor for advanced or metastatic breast cancer; GB261, a novel CD3/CD20 bispecific antibody which is in Phase III clinical trial for autoimmune diseases; and GB263T and GB268, tri-specific antibody candidates which are Phase I clinical trial. It also provides Vancocin for mult...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 2001
• Employees: 1,545
• Stock Exchange: Hong Kong Stock Exchange
• Ticker Symbol: 6998

Financial Performance

Financial numbers in CNY

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Aug 27, 2026

Data Sources Report a data error